TRANSCEND-T2D-1 reported results on March 19, 2026 the first Phase 3 diabetes readout: These trials are expected to further broaden retatrutide's potential label across metabolic, musculoskeletal, and liver disease indications
Among GLP-1 users, its MMS more than doubles to 1.5% and mental penetration climbs from 53% to 72%
Some patients may achieve adequate glycemic control or weight loss at this dose level, particularly those with mild metabolic dysfunction or those who are particularly sensitive to the medications effects
Zhang, V.X., Sze, K.M-F., Chan, L-K., Ho, D.W-H., Tsui, Y-M., Chiu, Y-T., Husain, A., Huang, H., Tian, L., Wong, C.C-L., Ng, I.O-L
Clinical trials show it could help people lose weight and improve their health
Key takeaways Ozempic (semaglutide) is a peptide, but not a biologic, because its structure contains fewer than 40 amino acids